Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Rami Manochakian

Sex Differences in Tolerability to Anti‐Programmed Cell Death Protein 1 Therapy in Patients With Metastatic Melanoma and Non‐Small Cell Lung Cancer: Are We All Equal?

Oncologist

English

Emerging Lung Cancer Therapeutic Targets Based on the Pathogenesis of Bone Metastases

International Journal of Cell Biology

Cell Biology

2014

English

Related publications

P1.01-17 Immune-Related Adverse Events in Patients With Metastatic Non-Small Cell Lung Cancer: Sex Differences and Response to Therapy

Journal of Thoracic Oncology

English

Real‐World Outcomes of Patients With Metastatic Non‐Small Cell Lung Cancer Treated With Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval

English

Prognostic Value of Red Blood Cell Distribution Width in Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death-1 Antibody

English

Cutaneous Adverse Events (AEs) of Anti-Programmed Cell Death (PD)-1 Therapy in Patients With Metastatic Melanoma: A Single-Institution Cohort

Journal of the American Academy of Dermatology

Dermatology

2016

English

Anti-Programmed Cell Death Protein-1/Ligand-1 Therapy in Different Cancers

British Journal of Cancer

Cancer Research

Oncology

2015

English

MicroRNAs Aid the Assessment of Programmed Death Ligand�1 Expression in Patients With Non‑small Cell Lung Cancer

English

Programmed Death-Ligand 1 Immunohistochemistry Testing for Non-Small Cell Lung Cancer in Practice

English

Prognostic Impact of CD8 and Programmed Death-Ligand 1 Expression in Patients With Resectable Non-Small Cell Lung Cancer

British Journal of Cancer

Cancer Research

Oncology

2019

English

Petals and Thorns in Programmed Death-Ligand 1 Testing: Is All Non-Small Cell Lung Cancer Diagnostic Material Suitable?

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Rami Manochakian

Sex Differences in Tolerability to Anti‐Programmed Cell Death Protein 1 Therapy in Patients With Metastatic Melanoma and Non‐Small Cell Lung Cancer: Are We All Equal?

Emerging Lung Cancer Therapeutic Targets Based on the Pathogenesis of Bone Metastases

Related publications

P1.01-17 Immune-Related Adverse Events in Patients With Metastatic Non-Small Cell Lung Cancer: Sex Differences and Response to Therapy

Real‐World Outcomes of Patients With Metastatic Non‐Small Cell Lung Cancer Treated With Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval

Prognostic Value of Red Blood Cell Distribution Width in Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death-1 Antibody

Cutaneous Adverse Events (AEs) of Anti-Programmed Cell Death (PD)-1 Therapy in Patients With Metastatic Melanoma: A Single-Institution Cohort

Anti-Programmed Cell Death Protein-1/Ligand-1 Therapy in Different Cancers

MicroRNAs Aid the Assessment of Programmed Death Ligand�1 Expression in Patients With Non‑small Cell Lung Cancer

Programmed Death-Ligand 1 Immunohistochemistry Testing for Non-Small Cell Lung Cancer in Practice

Prognostic Impact of CD8 and Programmed Death-Ligand 1 Expression in Patients With Resectable Non-Small Cell Lung Cancer

Petals and Thorns in Programmed Death-Ligand 1 Testing: Is All Non-Small Cell Lung Cancer Diagnostic Material Suitable?